92 research outputs found
The Iterative Signature Algorithm for the analysis of large scale gene expression data
We present a new approach for the analysis of genome-wide expression data.
Our method is designed to overcome the limitations of traditional techniques,
when applied to large-scale data. Rather than alloting each gene to a single
cluster, we assign both genes and conditions to context-dependent and
potentially overlapping transcription modules. We provide a rigorous definition
of a transcription module as the object to be retrieved from the expression
data. An efficient algorithm, that searches for the modules encoded in the data
by iteratively refining sets of genes and conditions until they match this
definition, is established. Each iteration involves a linear map, induced by
the normalized expression matrix, followed by the application of a threshold
function. We argue that our method is in fact a generalization of Singular
Value Decomposition, which corresponds to the special case where no threshold
is applied. We show analytically that for noisy expression data our approach
leads to better classification due to the implementation of the threshold. This
result is confirmed by numerical analyses based on in-silico expression data.
We discuss briefly results obtained by applying our algorithm to expression
data from the yeast S. cerevisiae.Comment: Latex, 36 pages, 8 figure
Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response
Background: In vitro models of prostate cancer (PCa) are not always reliable to evaluate anticancer treatment efficacy. This limitation may be overcome by using viable tumor slice material. Here we report on the establishment of an optimize
Shared Genetic Etiology Between Alcohol Dependence and Major Depressive Disorder
The clinical comorbidity of alcohol dependence (AD) and
major depressive disorder (MDD) is well established,
whereas genetic factors influencing co-occurrence remain
unclear. A recent study using polygenic risk scores (PRS)
calculated based on the first-wave Psychiatric Genomics
Consortium MDD meta-analysis (PGC-MDD1) suggests a
modest shared genetic contribution to MDD and AD. Using a
(âŒ10 fold) larger discovery sample, we calculated PRS
based on the second wave (PGC-MDD2) of results, in a
severe AD caseâcontrol target sample. We found significant associations between AD disease status and MDD-PRS derived from both PGC-MDD2 (most informative
P-threshold=1.0, P=0.00063, R2=0.533%) and PGCMDD1
(P-threshold=0.2, P=0.00014, R2=0.663%) metaanalyses;
the larger discovery sample did not yield
additional predictive power. In contrast, calculating PRS in a MDD target sample yielded increased power when using
PGC-MDD2 (P-threshold=1.0, P=0.000038, R2=1.34%)
versus PGC-MDD1 (P-threshold=1.0, P=0.0013,
R2=0.81%). Furthermore, when calculating PGC-MDD2
PRS in a subsample of patients with AD recruited explicitly excluding comorbid MDD, significant associations were still found (n=331; P-threshold=1.0, P=0.042, R2=0.398%). Meanwhile, in the subset of patients in which MDD was not the explicit exclusion criteria, PRS predicted more variance (n=999; P-threshold=1.0, P=0.0003, R2=0.693%). Our findings replicate the reported genetic overlap between AD and MDD and also suggest the need for improved, rigorous phenotyping to identify true shared cross-disorder genetic factors. Larger target samples are needed to reduce noise and take advantage of increasing discovery sample size
Common variants at 2q11.2, 8q21.3, and 11q13.2 are associated with major mood disorders
Bipolar disorder (BPD) and major depressive disorder (MDD) are primary major mood disorders. Recent studies suggest that they share certain psychopathological features and common risk genes, but unraveling the full genetic architecture underlying the risk of major mood disorders remains an important scientific task. The public genome-wide association study (GWAS) data sets offer the opportunity to examine this topic by utilizing large amounts of combined genetic data, which should ultimately allow a better understanding of the onset and development of these illnesses. Genome-wide meta-analysis was performed by combining two GWAS data sets on BPD and MDD (19,637 cases and 18,083 controls), followed by replication analyses for the loci of interest in independent 12,364 cases and 76,633 controls from additional samples that were not included in the two GWAS data sets. The single-nucleotide polymorphism (SNP) rs10791889 at 11q13.2 was significant in both discovery and replication samples. When combining all samples, this SNP and multiple other SNPs at 2q11.2 (rs717454), 8q21.3 (rs10103191), and 11q13.2 (rs2167457) exhibited genome-wide significant association with major mood disorders. The SNPs in 2q11.2 and 8q21.3 were novel risk SNPs that were not previously reported, and SNPs at 11q13.2 were in high LD with potential BPD risk SNPs implicated in a previous GWAS. The genome-wide significant loci at 2q11.2 and 11q13.2 exhibited strong effects on the mRNA expression of certain nearby genes in cerebellum. In conclusion, we have identified several novel loci associated with major mood disorders, adding further support for shared genetic risk between BPD and MDD. Our study highlights the necessity and importance of mining public data sets to explore risk genes for complex diseases such as mood disorders
ĐĐ±ĐœĐŸĐČĐ»Đ”ĐœĐœŃĐ” ŃĐ”ĐșĐŸĐŒĐ”ĐœĐŽĐ°ŃОО EULAR/ERAâEDTA 2019 Đł. ĐżĐŸ ŃĐ”ŃапОО ĐČĐŸĐ»ŃĐ°ĐœĐŸŃĐœĐŸĐłĐŸ ĐœĐ”ŃŃĐžŃĐ°. ĐĐŸĐŒĐŒĐ”ĐœŃĐ°ŃОО ŃĐșŃпДŃŃĐŸĐČ. ЧаŃŃŃ II
The paper presents the main provisions of the updated 2019 EULAR/ERA-EDTA guidelines for the lupus nephritis (LN) therapy, which have been prepared by an international group of rheumatologists, nephrologists, morphologists, and pediatricians. Part 2 of the article discusses additional therapy, monitoring, and prognosis for LN, and the management of patients with end-stage renal failure and antiphospholipid syndrome. Attention is paid to the problem of LN and pregnancy, as well as to the management of pediatric patients with kidney damage.ĐŃДЎŃŃĐ°ĐČĐ»Đ”ĐœŃ ĐŸŃĐœĐŸĐČĐœŃĐ” ĐżĐŸĐ»ĐŸĐ¶Đ”ĐœĐžŃ ĐŸĐ±ĐœĐŸĐČĐ»Đ”ĐœĐœŃŃ
ŃĐ”ĐșĐŸĐŒĐ”ĐœĐŽĐ°ŃĐžĐč EULAR/ERAâEDTA 2019 Đł. ĐżĐŸ ŃĐ”ŃапОО ĐČĐŸĐ»ŃĐ°ĐœĐŸŃĐœĐŸĐłĐŸ ĐœĐ”ŃŃĐžŃĐ° (ĐĐ), ĐżĐŸĐŽĐłĐŸŃĐŸĐČĐ»Đ”ĐœĐœŃŃ
ĐŒĐ”Đ¶ĐŽŃĐœĐ°ŃĐŸĐŽĐœĐŸĐč ĐłŃŃĐżĐżĐŸĐč ŃĐ”ĐČĐŒĐ°ŃĐŸĐ»ĐŸĐłĐŸĐČ, ĐœĐ”ŃŃĐŸĐ»ĐŸĐłĐŸĐČ, ĐŒĐŸŃŃĐŸĐ»ĐŸĐłĐŸĐČ Đž пДЎОаŃŃĐŸĐČ. ĐĐŸ ĐČŃĐŸŃĐŸĐč ŃĐ°ŃŃĐž ŃŃĐ°ŃŃĐž ĐŸĐ±ŃŃжЎаŃŃŃŃ ĐŽĐŸĐżĐŸĐ»ĐœĐžŃДлŃĐœĐ°Ń ŃĐ”ŃапОŃ, ĐŒĐŸĐœĐžŃĐŸŃĐžĐœĐł Đž ĐżŃĐŸĐłĐœĐŸĐ· ĐżŃĐž ĐĐ, ĐČĐŸĐżŃĐŸŃŃ ĐČĐ”ĐŽĐ”ĐœĐžŃ ĐżĐ°ŃĐžĐ”ĐœŃĐŸĐČ Ń ŃĐ”ŃĐŒĐžĐœĐ°Đ»ŃĐœĐŸĐč ĐżĐŸŃĐ”ŃĐœĐŸĐč ĐœĐ”ĐŽĐŸŃŃĐ°ŃĐŸŃĐœĐŸŃŃŃŃ, Đ°ĐœŃĐžŃĐŸŃŃĐŸĐ»ĐžĐżĐžĐŽĐœŃĐŒ ŃĐžĐœĐŽŃĐŸĐŒĐŸĐŒ. ĐŁĐŽĐ”Đ»Đ”ĐœĐŸ ĐČĐœĐžĐŒĐ°ĐœĐžĐ” ĐżŃĐŸĐ±Đ»Đ”ĐŒĐ” ĐĐ Đž бДŃĐ”ĐŒĐ”ĐœĐœĐŸŃŃĐž, Đ° ŃĐ°ĐșжД ŃĐ°ĐșŃĐžĐșĐ” ĐČĐ”ĐŽĐ”ĐœĐžŃ ĐżĐ°ŃĐžĐ”ĐœŃĐŸĐČ ĐŽĐ”ŃŃĐșĐŸĐłĐŸ ĐČĐŸĐ·ŃĐ°ŃŃĐ° Ń ĐżĐŸŃĐ°Đ¶Đ”ĐœĐžĐ”ĐŒ ĐżĐŸŃĐ”Đș
Identification of common genetic risk variants for autism spectrum disorder
Autism spectrum disorder (ASD) is a highly heritable and heterogeneous group of neurodevelopmental phenotypes diagnosed in more than 1% of children. Common genetic variants contribute substantially to ASD susceptibility, but to date no individual variants have been robustly associated with ASD. With a marked sample-size increase from a unique Danish population resource, we report a genome-wide association meta-analysis of 18,381 individuals with ASD and 27,969 controls that identified five genome-wide-significant loci. Leveraging GWAS results from three phenotypes with significantly overlapping genetic architectures (schizophrenia, major depression, and educational attainment), we identified seven additional loci shared with other traits at equally strict significance levels. Dissecting the polygenic architecture, we found both quantitative and qualitative polygenic heterogeneity across ASD subtypes. These results highlight biological insights, particularly relating to neuronal function and corticogenesis, and establish that GWAS performed at scale will be much more productive in the near term in ASD.Peer reviewe
Genome-wide association study identifies 30 Loci Associated with Bipolar Disorder
This paper is dedicated to the memory of Psychiatric Genomics Consortium (PGC) founding member and Bipolar disorder working group co-chair Pamela Sklar. We thank the participants who donated their time, experiences and DNA to this research, and to the clinical and scientific teams that worked with them. We are deeply indebted to the investigators who comprise the PGC. The views expressed are those of the authors and not necessarily those of any funding or regulatory body. Analyses were carried out on the NL Genetic Cluster Computer (http://www.geneticcluster.org ) hosted by SURFsara, and the Mount Sinai high performance computing cluster (http://hpc.mssm.edu).Bipolar disorder is a highly heritable psychiatric disorder. We performed a genome-wide association study including 20,352 cases and 31,358 controls of European descent, with follow-up analysis of 822 variants with P<1x10-4 in an additional 9,412 cases and 137,760 controls. Eight of the 19 variants that were genome-wide significant (GWS, p < 5x10-8) in the discovery GWAS were not GWS in the combined analysis, consistent with small effect sizes and limited power but also with genetic heterogeneity. In the combined analysis 30 loci were GWS including 20 novel loci. The significant loci contain genes encoding ion channels, neurotransmitter transporters and synaptic components. Pathway analysis revealed nine significantly enriched gene-sets including regulation of insulin secretion and endocannabinoid signaling. BDI is strongly genetically correlated with schizophrenia, driven by psychosis, whereas BDII is more strongly correlated with major depressive disorder. These findings address key clinical questions and provide potential new biological mechanisms for BD.This work was funded in part by the Brain and Behavior Research Foundation, Stanley Medical Research Institute, University of Michigan, Pritzker Neuropsychiatric Disorders Research Fund L.L.C., Marriot Foundation and the Mayo Clinic Center for Individualized Medicine, the NIMH Intramural Research Program; Canadian Institutes of Health Research; the UK Maudsley NHS Foundation Trust, NIHR, NRS, MRC, Wellcome Trust; European Research Council; German Ministry for Education and Research, German Research Foundation IZKF of MĂŒnster, Deutsche Forschungsgemeinschaft, ImmunoSensation, the Dr. Lisa-Oehler Foundation, University of Bonn; the Swiss National Science Foundation; French Foundation FondaMental and ANR; Spanish Ministerio de EconomĂa, CIBERSAM, Industria y Competitividad, European Regional Development Fund (ERDF), Generalitat de Catalunya, EU Horizon 2020 Research and Innovation Programme; BBMRI-NL; South-East Norway Regional Health Authority and Mrs. Throne-Holst; Swedish Research Council, Stockholm County Council, Söderström Foundation; Lundbeck Foundation, Aarhus University; Australia NHMRC, NSW Ministry of Health, Janette M O'Neil and Betty C Lynch
Translating big data to better treatment in bipolar disorder - a manifesto for coordinated action
Bipolar disorder (BD) is a major healthcare and socio-economic challenge. Despite its substantial burden on society, the research activity in BD is much smaller than its economic impact appears to demand. There is a consensus that the accurate identification of the underlying pathophysiology for BD is fundamental to realize major health benefits through better treatment and preventive regimens. However, to achieve these goals requires coordinated action and innovative approaches to boost the discovery of the neurobiological underpinnings of BD, and rapid translation of research findings into development and testing of better and more specific treatments. To this end, we here propose that only a large-scale coordinated action can be successful in integrating international big-data approaches with real-world clinical interventions. This could be achieved through the creation of a Global Bipolar Disorder Foundation, which could bring government, industry and philanthropy together in common cause. A global initiative for BD research would come at a highly opportune time given the seminal advances promised for our understanding of the genetic and brain basis of the disease and the obvious areas of unmet clinical need. Such an endeavour would embrace the principles of open science and see the strong involvement of user groups and integration of dissemi
Age at first birth in women is genetically associated with increased risk of schizophrenia
Prof. Paunio on PGC:n jÀsenPrevious studies have shown an increased risk for mental health problems in children born to both younger and older parents compared to children of average-aged parents. We previously used a novel design to reveal a latent mechanism of genetic association between schizophrenia and age at first birth in women (AFB). Here, we use independent data from the UK Biobank (N = 38,892) to replicate the finding of an association between predicted genetic risk of schizophrenia and AFB in women, and to estimate the genetic correlation between schizophrenia and AFB in women stratified into younger and older groups. We find evidence for an association between predicted genetic risk of schizophrenia and AFB in women (P-value = 1.12E-05), and we show genetic heterogeneity between younger and older AFB groups (P-value = 3.45E-03). The genetic correlation between schizophrenia and AFB in the younger AFB group is -0.16 (SE = 0.04) while that between schizophrenia and AFB in the older AFB group is 0.14 (SE = 0.08). Our results suggest that early, and perhaps also late, age at first birth in women is associated with increased genetic risk for schizophrenia in the UK Biobank sample. These findings contribute new insights into factors contributing to the complex bio-social risk architecture underpinning the association between parental age and offspring mental health.Peer reviewe
Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.
BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362
- âŠ